HEPARIN SODIUM INJECTION USP SOLUTION

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

HEPARIN SODIUM

Disponibbli minn:

PFIZER CANADA ULC

Kodiċi ATC:

B01AB01

INN (Isem Internazzjonali):

HEPARIN

Dożaġġ:

5000UNIT

Għamla farmaċewtika:

SOLUTION

Kompożizzjoni:

HEPARIN SODIUM 5000UNIT

Rotta amministrattiva:

INTRAVENOUS

Unitajiet fil-pakkett:

10ML/25X10ML

Tip ta 'preskrizzjoni:

Ethical

Żona terapewtika:

HEPARINS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0104596008; AHFS:

L-istatus ta 'awtorizzazzjoni:

CANCELLED POST MARKET

Data ta 'l-awtorizzazzjoni:

2015-06-01

Karatteristiċi tal-prodott

PRODUCT MONOGRAPH
HEPARIN SODIUM INJECTION USP
FOR INTRAVENOUS OR SUBCUTANEOUS USE
1000 USP UNITS PER ML (PRESERVATIVE FREE)
1000 USP UNITS PER ML
5 000 USP UNITS PER ML
10 000 USP UNITS PER ML
ANTICOAGULANT
Pfizer Canada Inc.
17300 Trans Canada Highway
Kirkland, Quebec
H9J 2M5
Control No.: 175574
Date of Revision: November 4, 2014
Date of Approval: December 16, 2014
_ _
Heparin Sodium Injection_ _USP _ _
Page 2 of 25_ _
Pfizer Canada Inc.
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
.....................................................................3
INDICATIONS AND CLINICAL USE
...........................................................................3
CONTRAINDICATIONS
.................................................................................................4
WARNINGS AND PRECAUTIONS
...............................................................................4
ADVERSE REACTIONS
..................................................................................................9
DRUG INTERACTIONS
................................................................................................11
DOSAGE AND ADMINISTRATION
...........................................................................13
OVERDOSAGE
...............................................................................................................16
ACTIONS AND CLINICAL PHARMACOLOGY
......................................................17
STORAGE AND
STABILITY........................................................................................18
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................18
PART II: SCIENTIFIC INFORMATION
................................................................................20
PHARMACEUTICAL INFORMATION
......................................................................20
CLINICAL TRIALS
.............................................................................